Thursday, March 16, 2017| , AAD, , Galderma, , Modernizing Medicine,

DermWireTV: AAD SkinSerious Campaign, Meeting Highlights; Galderma Partners with Modernizing Medicine

The American Academy of Dermatology’s new SkinSerious campaign is raising awareness about skin disease and the specialty. The Skin Serious initiative kicked off at the AAD Annual Meeting in Orlando this month. New research presented at this year’s meeting focused on skin disease prevention and treatment. Galderma and Moderning Medicine are teaming up for a new integrated OTC ecommerce platform designed by Modernizing Medicine to make it easier for healthcare providers to create materials about patient treatment regimens and provide product recommendations to patients. Pershing Square Capital Management—for which Bill Ackman is CEO—has sold its investment in Valeant Pharmaceuticals International.

Watch Video

Thursday, February 23, 2017

DermWireTV: Valeant's Siliq Cleared, AmSpa Survey, New Skin Cancer Imaging

The FDA has approved Valeant Pharmaceutical's Siliq (brodalumab) injection for subcutaneous use for patients with moderate-to-severe plaque psoriasis. The American Med Spa Association (AmSpa) has extended the deadline for its comprehensive survey of MedSpas nationwide. Multiphoton microscopy of mitochondria, a new non-invasive imaging technique, may accurately detect skin cancer without surgical biopsy. And we'll see you at the AAD.

Watch Video

Wednesday, February 08, 2017| , Galderma, , Valeant NJ, , Zeltiq,

Galderma's Differin Goes OTC, CoolSculpting Approved for Upper Arms, ZO Skin Acquires ReFissa

Galderma’s Differin Gel formulation of adapalene 0.1% is now available over the counter at major retail and drug stores in the US. ZELTIQ® Aesthetics’ CoolSculpting is now FDA-cleared for fat reduction in the upper arms. ZO Skin Health has acquired the worldwide rights to ReFissa from Suneva Medical. Valeant Dermatology will be awarding nine individual scholarships of up to $10,000 through its annual ASPIRE HIGHER Scholarship Program.

Watch Video

Thursday, January 26, 2017

DermWireTV: Rhofade Approved, Sun Leaves Acne Behind, Radiesse Turns 10

The FDA has approved Allergan's Rhofade (Oxymetazoline 1%) cream for the topical treatment of persistent facial erythema associated with rosacea in adults. New research from Olay in collaboration with personal genetics company 23andMe shows that taking care of the skin may be the key to looking up to 10 years younger. Research from Johnson & Johnson suggests that the combined use of sunscreen and a beach umbrella may be the best bet for skin protection. Sun Pharma is urging patients to “Leave Acne Behind with an awareness campaign for severe recalcitrant nodular acne (SRNA). With more than 6 million syringes sold worldwide, Radiesse from Merz Aesthetics marks its 10-year anniversary this year.

Watch Video

Thursday, January 12, 2017| , L'oreal, , Valeant NJ,

DermWireTV: L'Oreal Nabs CeraVe, Smart Beauty Tools, Skin Cancer Knowledge Lacking

Researchers from La Roche-Posay and the George Washington University Department of Dermatology find that citizens in Australia, Ireland, Brazile, and Greece are best educated about UV exposure risks. Americans scored about average, said study author Dr. Adam Friedman. Valeant has agreed to sell its CeraVe, AcneFree, and Ambi lines to L’oreal for 1.3 billion dollars in cash. Kérastase and Withings nabbed this year's International CES Innovation Award with The Kérastase Hair Coach Powered. HiMirror rolled out a new Plus edition. Samsung’s S-Skin “microneedle” patch penetrates the skin with ingredients and simultaneously captures measurements of skin quality.

Watch Video

Monday, December 19, 2016| , Galderma, , Valeant NJ,

DermWireTV: Humphries to Valeant, Restylane Line Expands, 2016 Highlights

The filler market in the US expands with FDA approval of Galderma’s Restylane Refyne and Restalyne Define for the treatment of nasolabial folds in patients over the age of 21. The gels are manufactured with XpresHAn Technology, which allows a range of flexibility and support for varied patient needs, the company says. Dermatology industry veteran William D. Humphries has been appointed Executive Vice President, Dermatology, at Valeant Pharmaceuticals effective January 2. And as 2016 comes to a close, we take a look at some of the notable approvals of the year.

Watch Video

Thursday, December 08, 2016| , Cosmetic surgery, , Cosmetic Surgery Forum,

DermWireTV: Michael Gold Honored, CSF Highlights, Anxiety Linked to Skin Disease

From bloodless blephs to nutraceuticals, innovative approaches to patient care take the spotlight at Cosmetic Surgery Forum each year. This year, the meeting introduced new topics and new speakers, says CSF founder and Practical Dermatology Chief Cosmetic Surgery Editor, Dr. Joel Schlessinger. Dr. Michael H. Gold, and leader in the application of dermatologic devices is this year’s recipient of the Lifetime Contribution to Aesthetics Award at Cosmetic Surgery Forum. The link between anxiety and skin disease is gaining new attention. Researchers have shown that skin disorders tend to crop up in teens after they manifest anxiety disorders. Banning indoor tanning for minors in the US could save millions of dollars and save thousands of lives, a new analysis suggests.

Watch Video

Thursday, November 10, 2016| , Eczema, , Psoriasis,

DermWireTV: Enbrel Gets Nod for Pediatric PsO; IL-33 Targeted in Itch

FDA approved Amgen's Enbrel (etanercept) for chronic moderate to severe psoriasis in pediatric patients age 4 to 17. DermCheck App partners with anti-bullying groups Pacer and Not In My Town to help fight bullying and expand acne care. Researchers show that anti-IL-33 antibody reduces itch of poison ivy in mice, and look ahead to human applications in dermatitis, eczema, and psoriasis.

Watch Video

Thursday, October 27, 2016| , Allergan , , Cosmetic surgery,

DermWireTV: Elections and Markets, Encore and Biofrontera Launches, More

Election years bring market uncertainty, but should you be making any changes to your portfolio now? Financial experts weigh in on why—no matter the results—there's no need for panic. Allergan launches a new campaign, ActuallySheCan, to empower young women. Several new products are now available for dermatology practitioners, including HylatopicPlus Lotion and Ameluz. Plus, new data from the Pew Research Center on the popularity of cosmetic surgery.

Watch Video

Wednesday, October 12, 2016| , Atopic Dermatitis , , Psoriasis,

DermWireTV: AD Impact, Allofill Comes to Market, GPA Launches

From sleep disruptions or negative impact on the ability to work to feelings of depression and anxiety, atopic dermatitis can have significant effects on adults, new research suggests. In fact, more than half of respondents to a Harris Poll say that AD has negatively impacted their daily lives. Doris Day, MD weighs in. The first-ever worldwide database on psoriasis, the Global Psoriasis Atlas has the backing of three global health organizations: the International Federation of Psoriasis Associations, the International League of Dermatological Societies, and the International Psoriasis Council. Allofill from Biologica Technologies, a ready-to-use, allograft-derived filler that retains the native extracellular matrix (ECM) components of allograft-derived adipose tissue, is now available.

Watch Video

Thursday, September 22, 2016| , Allergan , , Celgene, , National Psoriasis Foundation, , Psoriasis,

DermWireTV: Allergan Acquires Vitae, PsA Day, Novan News

Allergan is acquiring clinical-stage biotechnology company Vitae Pharmaceuticals for $21.00 per share, in cash, for a total transaction value of approximately $639 million. Novan has launched its initial public offering and is now listed on the NASDAQ. Celgene Corporation and the National Psoriasis Foundation are promoting the first-ever Psoriatic Arthritis Awareness Day to increase education, empowerment, and action for the psoriatic arthritis community. Nearly 25% of immigrant or minority participants in a recent survey say that they have never heard of skin cancer or melanoma, and more than half of participants had rarely or never performed skin self-exams. More on the study findings in DermWireTV.

Watch Video

Thursday, September 08, 2016

DermWireTV: Patient Outreach Initiatives; Erelzi Approved

DermatologistOnCall® Partners with NPF to enhance access to care for psoriasis. Vivacare Partners with NRS for patient education. Erelzi from Sandoz approved as biosimilar to Enbrel. And the FDA bans antibacterial ingredients from hand soaps; Calls for plain soap and water hand washing.

Watch Video
Load More